Gujarat Terce Laboratories Limited

GUJTERC6

INE499G01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:57 02/07/2024 pm IST			5-day change	1st Jan Change
46.99 ^INR	+4.31%		-6.95%	+64.94%

29/05	Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
29/03	Gujarat Terce Laboratories Limited announced that it expects to receive INR 3.496675 million in funding	CI

Gujarat Terce Laboratories Limited Appoints Natwarbhai Prajapati as Compliance Officer, Effective January 9, 2020

January 08, 2020 at 07:16 pm IST

Gujarat Terce Laboratories Limited at its board of directors meeting held on January 8, 2020 appointed Mr. Natwarbhai Prajapati as Compliance Officer of the Company with effect from 09 January, 2020.

Latest news about Gujarat Terce Laboratories Limited

Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	29/05	CI
Gujarat Terce Laboratories Limited announced that it expects to receive INR 3.496675 million in funding	29/03	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	05/02	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	13/23/13	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	13/23/13	CI
Gujarat Terce Laboratories Limited Approves Appointment of Ripal Sachinkumar Sukhadiya as the Company Secretary & Compliance Officer	07/23/07	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	31/23/31	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	31/23/31	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Gujarat Terce Laboratories Limited Announces Resignation of Ashka Solanki as Company Secretary and Compliance Officer	06/22/06	CI
Gujarat Terce Laboratories Limited Approves the Appointment of Natwarbhai Prajapati as the Whole Time Director	24/22/24	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	05/22/05	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/22/30	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/22/30	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	24/22/24	CI
Gujarat Terce Laboratories Appoints New CEO	29/21/29	MT
Gujarat Terce Laboratories CEO Resigns	28/21/28	MT
Gujarat Terce Laboratories Limited Announces Resignation of Natwarbhai Prajapati as Managing Director	28/21/28	CI
Gujarat Terce Laboratories Limited Announces Executive Changes	28/21/28	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	28/21/28	CI
Gujarat Terce Laboratories : Turns to Profit in Fiscal Q1	23/21/23	MT
Gujarat Terce Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	23/21/23	CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	24/21/24	CI

Chart Gujarat Terce Laboratories Limited

Duration

Period

Chart Gujarat Terce Laboratories Limited

More charts

Gujarat Terce Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of medicines and healthcare products. Its diverse portfolio encompasses approximately 70 brands and 180 stock-keeping units (SKUs) covering multiple dosage forms, such as tablets, capsules, oral liquids, ointments and injectables. The Company offers therapies in areas of antibiotics, gynecology, respiratory, nutraceuticals, gastrointestinal and anti-fungal. The Companyâs brands include Acolate, Codimol, Resplash, Terflora Z, Thyter, Tynol, Z-Oxi, and Vitfol. The Company has approximately eight brands occupying a space in the top 10 in various therapeutic areas. The Company has a presence in over 13 states in India. The Company also has a presence in Eastern and Western Africa, the association of Southeast Asian Nations (ASEAN), and Latin American (LATAM) countries.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
GUJARAT TERCE LABORATORIES LIMITED	+64.94%	4.01M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.01%	43.7B
OTSUKA HOLDINGS CO., LTD.	+28.76%	23.11B
SANDOZ GROUP AG	+20.07%	15.43B
CIPLA LIMITED	+19.45%	14.31B
ZYDUS LIFESCIENCES LIMITED	+55.92%	12.87B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.46%	6.45B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.00%	5.55B